TB-500
peptide · headline503A · PCAC-pendingPromotes cell migration
Overview
TB-500 is a synthetic peptide modeled after Thymosin Beta-4 that promotes tissue regeneration, reduces inflammation, and supports recovery in musculoskeletal injuries. It is often used by researchers and clinicians for its potent actin-binding properties and ability to enhance healing in muscles, tendons, ligaments, and even cardiac tissue.
How it works
- Promotes cell migration
- Enhances collagen deposition
- Reduces inflammation
- Upregulates actin-binding proteins to enhance cytoskeletal repair
- Improves angiogenesis and tissue oxygenation
- Supports endothelial integrity and cardiac repair
Dosing
Standard dose: 2.5 mg SubQ every other day for 4-6 weeks (loading), then 2 mg weekly (maintenance).
Caution: In preclinical studies, TB-500 has been administered at 2.0 mg per week (typically divided into two doses), depending on the animal model and tissue target. These regimens are investigational and not authorized for human application..
Cycling
- Loading Phase: 2.5 mg subQ injection every other day for 4–6 weeks. Maintenance Phase: 2 mg subQ injection once weekly.
Side effects
- Common
- Headaches, especially first few days
- Slight energy drop early in treatment
- Warnings
- Possible BP decreases, dizziness, palpitations at higher doses
- Anaphylaxis risk in hypersensitive individuals
Stacking & combinations
- With
BPC-157
- Benefit
Enhanced injury recovery
- With
CJC-1295
- Benefit
Muscle growth and recovery synergy
Lifestyle support
- Diet
Adequate protein for tissue repair.
- Sleep
Sleep 7–9 hours. Stress management.
- Timing
2x weekly during loading, then weekly maintenance.
- Exercise
Balance activity and rest during injury recovery.
Research studies
Studies summarized for educational purposes only. Inclusion does not imply human use; referenced research was conducted in vitro, in animal models, or in regulated clinical trials.
Thymosin β4: a multi-functional regenerative peptide. Indications for use in clinical trials
Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Expert Opin Biol Ther. 2012;12(1):37–51. View source ↗
This review synthesizes the molecular biology of Thymosin Beta-4 and its observed activities in preclinical models. The authors describe Tβ4's primary intracellular role as a G-actin sequestering protein that regulates cytoskeletal dynamics, and its secreted activities including modulation of stem and progenitor cell migration, angiogenesis via VEGF and laminin pathways, and downregulation of pro-inflammatory cytokines. The review summarizes preclinical evidence across dermal, corneal, cardiac, and central nervous system injury models, where systemic or topical Tβ4 administration was associated with accelerated repair and reduced inflammatory infiltrate.
Researchers reviewed everything known at the time about Thymosin Beta-4 — the peptide that TB-500 is the synthetic version of. Inside cells, it acts like a manager that organizes the cell's internal scaffolding. When it's released outside the cell, it appears to help wound healing in multiple ways: it helps stem cells move to where they're needed, helps new blood vessels form, and quiets the inflammation signals that can slow repair. Animal studies in skin, eye, heart, and brain injury models all showed signs of faster recovery when Tβ4 was given.
Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization
Smart N, Risebro CA, Melville AA, Moses K, Schwartz RJ, Chien KR, Riley PR. Nature. 2007;445(7124):177–82. View source ↗
Using genetic lineage tracing in adult mice, the authors demonstrated that Thymosin Beta-4 administration mobilized quiescent epicardium-derived progenitor cells, inducing their proliferation, migration into the myocardium, and differentiation toward endothelial fates. The result was increased capillary density in regions of cardiac injury. The effect required functional Tβ4 and was associated with restoration of pluripotency markers in adult epicardial cells, suggesting that Tβ4 reactivates a developmental program normally dormant in adult tissue.
Scientists studied how Thymosin Beta-4 affects the outer layer of the heart in adult mice. They found that the peptide woke up sleeping stem-like cells in this layer, made them divide, and prompted them to migrate into damaged heart tissue where they started forming new blood vessels. In effect, Tβ4 seemed to switch on a repair program that the adult heart had stopped using since development.
Verified citations
2 · PubMed-checked- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.reviewPMID 41490200 ↗
- Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.reviewPMID 41476424 ↗
Reconstitution calculator
Subcutaneous (SQ)= 0.5 mL on a U-100 insulin syringe
Assumes a U-100 insulin syringe (100 units = 1 mL). This is a preparation aid, not a protocol — dose and route are the prescriber's decision. Refrigerate at 2–8 °C (35.6–46.4 °F); do not freeze reconstituted solution as freezing can denature peptides
Chemistry & PK
- Sequence
- Ac-Ser-Asp-Lys-Pro-Thr-Phe-Ser-Pro-Lys-Glu-Lys-Lys-Cys-Asp-Glu-Leu-Ser-Kys-Leu-Tyr-Glu-Asp-Gly-Asp-Tyr-Phe-Ser-Asp-Cys-Phe-Leu-Cys-His-Val
- Half Life
- 1–2 days
- Degradation
- Metabolized primarily in the liver.
- Molecular Weight
- 4963.49
- Molecular Formula
- C212H350N56O78S
- Tissue Specificity
- Affects muscle, connective tissues, and tendons.
Bioavailability
- In
- Intramuscular delivery is equally or more effective than SubQ for local injuries.
- Oral
- Poor due to enzymatic degradation in the digestive system.
- Subq
- Generally high and effective for systemic action.
Storage & handling
- Lyophilized
store at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); do not freeze reconstituted solution
- Reconstituted
Refrigerate at 2–8 °C (35.6–46.4 °F); do not freeze reconstituted solution as freezing can denature peptides
Used for
No condition evidence rows yet.
Legal / compounding
- EU
- Not Approved
- FDA
- Not Approved
- Canada
- Not Approved
- Australia
- Not Approved
Legal status is a hard gate: non-compoundable or delisted agents cannot be filled and are blocked from protocol export. Keep 503A status current.